Inotiv, Inc. - Common Stock (NOTV)
2.8700
+0.4600 (19.09%)
NASDAQ · Last Trade: Apr 2nd, 9:14 PM EDT
Detailed Quote
Previous Close | 2.410 |
---|---|
Open | 2.360 |
Bid | 2.510 |
Ask | 2.600 |
Day's Range | 2.340 - 2.890 |
52 Week Range | 1.227 - 11.20 |
Volume | 808,975 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 600,191 |
About Inotiv, Inc. - Common Stock (NOTV)
Inotiv Inc is a leading provider of preclinical and clinical research services, specializing in laboratory animal research and drug development solutions for the pharmaceutical and biotechnology industries. The company offers a wide range of scientific services, including toxicology, pathology, and pharmacology, aimed at helping clients navigate the complexities of medical research and bring new therapies to market. By leveraging advanced technologies and expertise, Inotiv supports clients in designing and executing studies that ensure the safety and efficacy of therapeutic products, thereby advancing healthcare innovation. Read More
News & Press Releases

Insider buying is a signal to buy for two of the stocks on this list, insider selling raises a red flag for the other but doesn't offset institutional activity.
Via MarketBeat · March 6, 2025

Via Benzinga · November 8, 2024

Via Benzinga · November 5, 2024

NOTV stock results show that Inotiv missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
Via InvestorPlace · August 8, 2024

Explore three breakout stocks for potential growth and profitability in life sciences tools, semiconductors, and industrial machinery.
Via InvestorPlace · July 9, 2024

Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software.
Via InvestorPlace · July 1, 2024

Via Benzinga · June 3, 2024

Via Benzinga · May 20, 2024

The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
By Kirby McInerney LLP · Via Business Wire · May 16, 2024

NOTV stock results show that Inotiv missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · May 15, 2024

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of Inotiv stockholders. Our investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · May 16, 2024

Via Benzinga · May 15, 2024

Via Benzinga · May 14, 2024

Via Benzinga · May 14, 2024

Augmedix stock is down on Tuesday as investors in AUGX shares are unimpressed with the company's updated revenue outlook for 2024!
Via InvestorPlace · May 14, 2024

Via Benzinga · May 14, 2024

Inotiv stock is down on Tuesday after the company posted preliminary earnings results that failed to impress NOTV investors.
Via InvestorPlace · May 14, 2024

Via Benzinga · May 14, 2024

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Tuesday morning!
Via InvestorPlace · May 14, 2024